Terns Pharmaceuticals, Inc. 8-K

What Happened

• On January 7, 2026, Terns Pharmaceuticals issued a press release outlining its 2026 priorities and program milestones that management planned to present at the 44th Annual J.P. Morgan Healthcare Conference. The release also provided an update on the company’s unaudited cash, cash equivalents and marketable securities as of December 31, 2025. The company filed the press release as Exhibit 99.1 to its Form 8‑K filed January 9, 2026.

Key Details

• Press release date: January 7, 2026; Form 8‑K filed: January 9, 2026 (Item 2.02 – Results of Operations and Financial Condition).
• Topic of presentation: 2026 priorities and program milestones to be discussed at the 44th Annual J.P. Morgan Healthcare Conference.
• Financial update: the release included an unaudited update of cash, cash equivalents and marketable securities for the year ended December 31, 2025 (the filing attaches the full press release as Exhibit 99.1).

Why It Matters

• Cash balance and marketable securities updates give investors a snapshot of Terns’ financial runway and ability to fund clinical programs and operations into 2026.
• The outlined 2026 priorities and program milestones indicate near‑term catalysts and what management will emphasize at the J.P. Morgan conference, which can affect investor expectations and stock volatility.
• The press release is available in full via the attached exhibit for investors seeking specific figures and milestone timelines.